462 related articles for article (PubMed ID: 26683263)
1. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M; Tokunaga S; Uchida S; Sakoda M; Shirabe K; Beppu T; Emi Y; Oki E; Ueno S; Eguchi S; Akagi Y; Ogata Y; Baba H; Natsugoe S; Maehara Y;
Eur J Surg Oncol; 2016 Feb; 42(2):184-9. PubMed ID: 26683263
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
3. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T; Emi Y; Tokunaga S; Oki E; Shirabe K; Ueno S; Kuramoto M; Kabashima A; Takahashi I; Samura H; Eguchi S; Akagi Y; Natsugoe S; Ogata Y; Kakeji Y; Baba H; Maehara Y;
Anticancer Res; 2014 Nov; 34(11):6655-62. PubMed ID: 25368271
[TBL] [Abstract][Full Text] [Related]
4. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T; Shibata Y; Tojima Y; Tsuboi K; Sakamoto E; Kunieda K; Matsuoka H; Suzumura K; Sato M; Naganuma T; Sakamoto J; Morita S; Kondo K
Int J Clin Oncol; 2013 Apr; 18(2):335-42. PubMed ID: 22383023
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
10. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
11. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
13. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
14. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Jakab F
Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
16. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Tanaka K; Nojiri K; Kumamoto T; Takeda K; Endo I
Eur J Surg Oncol; 2011 Apr; 37(4):336-43. PubMed ID: 21277151
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
18. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Hebbar M; Pruvot FR; Romano O; Triboulet JP; de Gramont A
Cancer Treat Rev; 2009 Dec; 35(8):668-75. PubMed ID: 19733977
[TBL] [Abstract][Full Text] [Related]
19. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
20. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
Alberts S; Poston G
Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
